Inventor · disambiguated record

Pasi Janne

Also filed as: JANNE PASI · JANNE PASI A · JANNE PASI ANTERO · JÄNNE PASI A

32 granted patents·17 pending applications·537 citations·filing 2005–2023

96Inventor score

Technology areasA61P C07D A61K G01N C12Q

Files withDANA FARBER CANCER INST INC36 GEN HOSPITAL CORP3 MASSACHUSETTS GEN HOSPITAL3 BELL DAPHNE WINIFRED2 BRIGHAM & WOMENS HOSPITAL1

Top patents by PatentIndex Score

49 records

0198US7964349B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2007·Granted Jun 21, 2011·92 cites·31 claims
0298US7294468B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2005·Granted Nov 13, 2007·187 cites·8 claims
0397US9758522B2Hydrophobically tagged small molecules as inducers of protein degradationDANA FARBER CANCER INST INC·Filed 2013·Granted Sep 12, 2017·27 cites·22 claims
0496US8465916B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsBELL DAPHNE WINIFRED·Filed 2007·Granted Jun 18, 2013·85 cites·21 claims
0596US8105769B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsBELL DAPHNE WINIFRED·Filed 2007·Granted Jan 31, 2012·97 cites·4 claims
0692USRE48175EHydrophobically tagged small molecules as inducers of protein degradationDANA-FARBER CANCER INSTITUTE INC·Filed 2013·Granted Aug 25, 2020·9 cites·25 claims
0789US9035036B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2013·Granted May 19, 2015·8 cites·26 claims
0888US9908884B2EGFR inhibitors and methods of treating disordersGRAY NATHANAEL S·Filed 2010·Granted Mar 6, 2018·12 cites·5 claims
0986US10450310B2Bifunctional molecules for degradation of EGFR and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 22, 2019·5 cites·18 claims
1082US12331037B2Pyrimidines as EGFR-inhibitors and methods of treating disordersDANA FARBER CANCER INST INC·Filed 2023·Granted Jun 17, 2025·0 cites·16 claims
1182US8715665B2Methods for treating cancer resistant to ErbB therapeuticsJANNE PASI A·Filed 2008·Granted May 6, 2014·10 cites·12 claims
1280US10266517B2Pyrimidines as EGFR inhibitors and methods of treating disordersDANA FARBER CANCER INST INC·Filed 2015·Granted Apr 23, 2019·2 cites·18 claims
1379US10836722B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 17, 2020·1 cites·18 claims
1478US10385019B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Aug 20, 2019·2 cites·21 claims
1575US12006555B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Jun 11, 2024·0 cites·16 claims
1673US11858897B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2021·Granted Jan 2, 2024·0 cites·7 claims
1773US10669589B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Jun 2, 2020·0 cites·13 claims
1871US11673882B2Pyrimidines as EGFR inhibitors and methods of treating disordersDANA FARBER CANCER INST INC·Filed 2020·Granted Jun 13, 2023·0 cites·16 claims
1968US12233128B2Degraders that target ALK and therapeutic uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 25, 2025·0 cites·7 claims
2068US2022017510A1Bifunctional molecules for degradation of egfr and methods of useDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
2167US11161842B2Bifunctional molecules for degradation of EGFR and methods of useDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 2, 2021·0 cites·19 claims
2267US11066363B2Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2019·Granted Jul 20, 2021·0 cites·6 claims
2367US11009508B2Methods of diagnosing and prognosing lung cancerDANA FARBER CANCER INST INC·Filed 2019·Granted May 18, 2021·0 cites·15 claims
2466US2021094913A1Inhibitors of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
2564US10870636B2Pyrimidines as EGFR inhibitors and methods of treating disordersDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 22, 2020·0 cites·18 claims
2663US11945816B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
2763US2018354954A9Hydrophobically tagged small molecules as inducers of protein degradationDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
2860US11008620B2Methods for treating cancer resistant to ErbB therapeuticsDANA FARBER CANCER INST INC·Filed 2015·Granted May 18, 2021·0 cites·20 claims
2960US10508082B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2016·Granted Dec 17, 2019·0 cites·17 claims
3060US2024209371A1Compositions and methods for treating cancerDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
3159US10000815B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2015·Granted Jun 19, 2018·0 cites·32 claims
3257US10865451B2Non-invasive blood based monitoring of genomic alterations in cancerDANA FARBER CANCER INST INC·Filed 2014·Granted Dec 15, 2020·0 cites·26 claims
3355US11186574B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 30, 2021·0 cites·20 claims
3455US2022090203A9Non-invasive blood based monitoring of genomic alterations in cancerDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
3555US2014296100A1Methods for treating cancer resistant to erbb therapeuticsDANA FARBER CANCER INST INC·Filed 2014·Application pending·0 cites
3650US2019040065A1EGFR Inhibitors and Methods of Treating DisordersDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
3750US2011110923A1Fish assay for eml4 and alk fusion in lung cancerBRIGHAM & WOMENS HOSPITAL·Filed 2009·Application pending·0 cites
3848US2020377501A1Degraders of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
3948US2011119776A1Methods of diagnosing and prognosing lung cancerWONG KWOK-KIN·Filed 2008·Application pending·0 cites
4047US11814379B2Cyano quinoline amide compounds as HER2 inhibitors and methods of useDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 14, 2023·0 cites·19 claims
4143US11584746B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 21, 2023·0 cites·22 claims
4243US10550112B2Pyrimidines as EGFR inhibitors and methods of treating disordersDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 4, 2020·0 cites·25 claims
4343US2021085688A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
4442US2020375999A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
4542US2021077469A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
4641US2020390783A1Inhibitors of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
4741US2020377477A1Degraders of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
4838US2019016703A1Bifunctional compounds for her3 degradation and methods of useDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
4937US2020216454A1Bifunctional molecules for her3 degradation and methods of useDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Pasi Janne files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →